ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0329

Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0114

Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0298

RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0372

Readability Analysis of the American College of Rheumatology Patient Education Material

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0586

Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0249

Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0508

Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0594

Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0168

Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0299

Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0214

Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0248

Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0033

Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0115

Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0757

Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].